Bulløse hudsygdomme

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Bulløse hudsygdomme. / Kaae, Jeanette; Bech, Rikke; Taudorf, Elisabeth Hjardem; Beck, Shiva; Vestergaard, Christian; Ring, Hans Christian; Jemec, Gregor B.

I: Ugeskrift for Laeger, Bind 184, Nr. 41, V06220400, 2022.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Kaae, J, Bech, R, Taudorf, EH, Beck, S, Vestergaard, C, Ring, HC & Jemec, GB 2022, 'Bulløse hudsygdomme', Ugeskrift for Laeger, bind 184, nr. 41, V06220400. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-09/v06220400_web.pdf>

APA

Kaae, J., Bech, R., Taudorf, E. H., Beck, S., Vestergaard, C., Ring, H. C., & Jemec, G. B. (2022). Bulløse hudsygdomme. Ugeskrift for Laeger, 184(41), [V06220400]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-09/v06220400_web.pdf

Vancouver

Kaae J, Bech R, Taudorf EH, Beck S, Vestergaard C, Ring HC o.a. Bulløse hudsygdomme. Ugeskrift for Laeger. 2022;184(41). V06220400.

Author

Kaae, Jeanette ; Bech, Rikke ; Taudorf, Elisabeth Hjardem ; Beck, Shiva ; Vestergaard, Christian ; Ring, Hans Christian ; Jemec, Gregor B. / Bulløse hudsygdomme. I: Ugeskrift for Laeger. 2022 ; Bind 184, Nr. 41.

Bibtex

@article{9b1ede31a26240068ae29ce34ec9aba6,
title = "Bull{\o}se hudsygdomme",
abstract = "This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.",
keywords = "Autoimmune Diseases, Azathioprine/adverse effects, Glucocorticoids, Humans, Methotrexate/adverse effects, Pemphigus/chemically induced, Rituximab/therapeutic use, Skin Diseases, Vesiculobullous/chemically induced",
author = "Jeanette Kaae and Rikke Bech and Taudorf, {Elisabeth Hjardem} and Shiva Beck and Christian Vestergaard and Ring, {Hans Christian} and Jemec, {Gregor B}",
year = "2022",
language = "Dansk",
volume = "184",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "41",

}

RIS

TY - JOUR

T1 - Bulløse hudsygdomme

AU - Kaae, Jeanette

AU - Bech, Rikke

AU - Taudorf, Elisabeth Hjardem

AU - Beck, Shiva

AU - Vestergaard, Christian

AU - Ring, Hans Christian

AU - Jemec, Gregor B

PY - 2022

Y1 - 2022

N2 - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.

AB - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.

KW - Autoimmune Diseases

KW - Azathioprine/adverse effects

KW - Glucocorticoids

KW - Humans

KW - Methotrexate/adverse effects

KW - Pemphigus/chemically induced

KW - Rituximab/therapeutic use

KW - Skin Diseases, Vesiculobullous/chemically induced

M3 - Review

C2 - 36254827

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 41

M1 - V06220400

ER -

ID: 326028285